Assertio Holdings Inc ASRT shares are trading higher by 12.48% to $3.27 Monday morning, rebounding following Friday's weakness, after the company reported second-quarter financial results and withdrew its 2023 financial outlook to "assess the recent news of a generic indomethacin suppository approved by the U.S. FDA."
Thursday, Zydus Lifesciences Limited received final approval from the FDA to manufacture and market Indomethacin suppositories, 50mg.
Zydus' Indomethacin suppositories, 50 mg, is the generic version of the Reference Listed Drug Indocin suppositories.
For its Indomethacin suppositories, the FDA has granted Zydus a CGT designation. Zydus' Indomethacin suppositories have also been granted 180-day CGT exclusivity to market this product...Read More
According to data from Benzinga Pro, ASRT has a 52-week high of $8.01 and a 52-week low of $2.07.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
